Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

John Harsh, PhD, clinical research director, Colorado Sleep Institute, sat down at SLEEP 2023 to discuss the RESTORE study results, and why patients with narcolepsy appear to prefer once-nightly sodium oxybate.

How Once-Nightly Sodium Oxybate Changes the Treatment Landscape for Narcolepsy

Videos

The sleep epidemiologist and assistant professor at the Rollins School of Public Health at Emory University, insight on the associations between race, socioeconomic backgrounds, and poor sleep and insufficient sleep. [WATCH TIME: 2 minutes]

The Impact of Social and Environmental Determinants, Race on Sleep: Dayna Johnson, PhD, MPH, MSW, MS

The hold comes nearly a month after Health Canada sent PepGen a No Objection Letter to start its phase 2 CONNECT1-EDO51 trial in patients with Duchenne muscular dystrophy.

FDA Places Hold on Phase 1 Study of Exon Skipping Therapy PGN-EDODM1 in Myotonic Muscular Dystrophy

After discussions with the FDA, the study will assess 2 co-primary end points of change in Rett Syndrome Behavior Questionnaire total score and Clinical Global Impression Improvement Scale score.

Phase 2/3 Study of Blarcamesine in Pediatrics With Rett Syndrome Completes Enrollment 

The professor of neurology at the University of Virginia discussed the progress made in recognizing and diagnosing neuromyelitis optica spectrum disorder through the discovery of specific monoclonal antibodies. [WATCH TIME: 5 minutes]

Diagnosis and Preventive Treatment Approaches in Managing NMOSD: Brian G. Weinshenker, MD, FRCP

Vice Chairman, Department of Neurology; Director, Movement Disorders Program; 

Medical Director, Georgetown University Hospital National Parkinsonism Foundation Center of Excellence; 

Medical Director, Translational Neurotherapeutics Program; 

Associate Professor, Department of Neurology, Georgetown University

The course director of ATMRD 2023 provided perspective on the notable strides made in the movement disorder field, including the significant progress made in drug delivery. [WATCH TIME: 5 minutes]

Recent Advances in Movement Disorders: Fernando Pagan, MD

The course directors of the 2023 ATRMD Congress provided an overview of the upcoming meeting, and the educational benefits clinicians can gain from attending. [WATCH TIME: 6 minutes]

Reasons to Attend the 2023 Advanced Therapeutics in Movement & Related Disorders Congress: Fernando Pagan, MD; Yasar Torres-Yaghi, MD

, has been with the team since September 2022. Follow her on Twitter 

Carolyn H. Goldschmidt, DO, a neurologist at NorthShore University Health System in Chicago, talked about a retrospective study analyzing disease-modifying therapies in multiple sclerosis patients at CMSC 2023.

Bridging the Gap, De-Escalation of MS Disease Modifying Therapies: Carolyn H Goldschmidt, DO

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

ATMRD 2023

Ataxia

CMSC 2023

NMOSD

Narcolepsy

Parkinson Disease

SLEEP 2023

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

Authors

Parkinson’s Disease and Movement Disorders Center, Baylor College of Medicine, Houston, TX

Psychosis is estimated to affect more than half of patients with Parkinson disease, and there is a growing need for improved management and therapeutic development.

Managing Nonmotor Symptoms: Psychosis in Parkinson Disease

Abhishek Lenka, MD, PhD

Articles